BioSpace News Archive

Medtronic plc, the global leader in medical technology, announced that it will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, 2019, in Rancho Palos Verdes, California.

Therigy® announced the launch of a new robust reporting tool: TherigyInsights.

Orchard Therapeutics, Fondazione Telethon and Ospedale San Raffaele announced that Orchard has been granted an exclusive worldwide license to intellectual property rights to research, develop, manufacture and commercialize the ex vivo autologous hematopoietic stem cell (HSC) gene therapy program for the treatment of Mucopolysaccharidosis Type I (MPS-I) developed by the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.

Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia, have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.

The deal broadens their work together from three to six programs for rare genetic diseases, as well as rights to collaborative R&D of novel gene therapies for lysosomal disorders and 12 additional rare diseases.

Orchard sees the gene therapy acquired as a potential treatment to “fundamentally change the lives of patients” who are born with this debilitating condition.

The primary endpoint of the trial was a three-point or greater improvement from baseline on the daily 24 hour Worst Itching Intensity Numeric Rating Scale (WI-NRS) score at week 12. In the trial, the score was 51% compared to 28% for patients receiving placebo.

The company’s board of directors hasn’t made a final decision to proceed with the listing.

Medtronic plc announced U.S. Food and Drug Administration clearance and commercial launch for the SelectSite C304-HIS deflectable catheter system for use in procedures involving His-bundle pacing.

The U.S. Food and Drug Administration approved Celgene’s Revlimid (lenalidomide) in combination with a rituximab product for adults with previously treated follicular lymphoma or marginal zone lymphoma. It is the first FDA-approved combination therapy for patients with these forms of non-Hodgkin’s lymphoma that doesn’t include chemotherapy.